Purpose: We reviewed the literature on adjuvant therapies for patients with high risk localized kidney cancer following surgical resection. In this analysis we merge 2 recently published prospective trials with conflicting results within the context of their respective designs. In addition, we spotlight upcoming trials that use novel immunotherapy based checkpoint inhibitors and have the potential to establish a new standard of care. Materials and Methods: We searched PubMed Ò for English language articles published through January 2017 using the keywords "renal cell carcinoma," "kidney cancer," "immunotherapy," "targeted therapy" and "adjuvant therapy." ClinicalTrials.gov was queried for ongoing studies. Relevant data recently presented at major urology and medical oncology meetings are also included. Results: Adjuvant therapies for high risk localized kidney cancer can be grouped into the categories of 1) traditional immunotherapy, 2) inhibitors of the vascular endothelial growth factor and mTOR (mammalian target of rapamycin) pathways, 3) vaccines and antibody dependent cytotoxic agents, and 4) immune checkpoint inhibitors. Several trials of traditional immunotherapy, such as interferon-a and high dose interleukin-2, failed to demonstrate benefit as adjuvant treatment and were associated with significant adverse events. Vascular endothelial growth factor and mTOR inhibitors have less severe toxicity in metastatic disease and, therefore, are natural considerations for adjuvant trials. However, current data are conflicting. The ASSURE (Sunitinib Malate or Sorafenib Tosylate in Treating Patients with Kidney Cancer that was Removed by Surgery, NCT00326898) trial found no recurrence-free survival benefit of sorafenib or sunitinib over placebo, No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. impressive efficacy and tolerability as second line agents in metastatic disease. Future adjuvant trials are likely to be guided by molecular signatures to treat patients most likely to benefit. Conclusions: Based on the available data, there appears to be no role for traditional immunotherapy as adjuvant treatment in patients with high risk localized kidney cancer following surgical resection. S-TRAC provides evidence that 1 year of adjuvant sunitinib in patients with higher risk locoregional disease increases the median time to recurrence. However, the data on overall survival are immature and adverse effects are common. Results from trials investigating immune checkpoint inhibitors are highly anticipated.
IN the current era of incidental, imaging based diagnoses of small kidney tumors complete surgical resection often results in cure. 1 The 5-year cancer specific survival for patients with stage I disease is greater than 90%. 1, 2 However, late relapse in the form of local and even distant disease is not uncommon. In a study of nearly 1,500 patients undergoing radical nephrectomy with a median followup of 10 years 5% and 15% experienced local and distant metastatic recurrence, respectively. 3 Disease may recur in as many as 35% to 40% of patients harboring high risk features. Recurrence rates in lymph node positive cases can be as high as 80%. 4 Once the disease progresses to a metastatic state, only high dose interleukin-2 has been shown to produce durable complete responses. 5 As such, there is interest in development of effective adjuvant therapies to prevent or delay relapse in patients with high risk disease.
Trials aimed at developing an effective adjuvant therapy for surgically resected kidney cancer date back several decades (supplementary table, http:// jurology.com/). Several negative trials evaluating a variety of treatment strategies have since dimmed the prospect of a successful adjuvant therapy. However, a recently published prospective study, S-TRAC, demonstrated improvement in DFS in patients with advanced locoregional kidney cancer taking sunitinib for 1 year. 6 These results, in combination with highly anticipated trials using immune checkpoint inhibitors, have reinvigorated hope for the use of adjuvant therapy in appropriately selected patients with a high risk of recurrence following surgical treatment.
In this review we provide context by describing the history and development of adjuvant therapy as it relates to other malignancies. We also review the natural history of high risk kidney cancer following surgical resection, discuss strategies used to identify patients who may require adjuvant treatment and explore the evolution of adjuvant therapies (see figure) . We categorize adjuvant therapies into groups consisting of 1) traditional immunotherapy, 2) inhibitors of VEGF and mTOR pathways, 3) vaccines and antibody dependent cytotoxic agents, and 4) immune checkpoint inhibitors. For each category evidence of efficacy in the metastatic setting is reviewed as these data generally provide rationale for subsequent adjuvant studies. We then analyze the results of prospective clinical trials testing adjuvant therapies in patients with high risk localized kidney cancer. Finally, we discuss ongoing and upcoming studies, particularly highly anticipated future trials using immune checkpoint inhibitors.
ADJUVANT THERAPY History and Development of Adjuvant Therapy
The goal of adjuvant therapy is to decrease the risk of recurrence by treating unrecognized micrometastatic residual disease. The concept of adjuvant therapy following tumor resection has been explored in numerous specialties, including genitourinary oncology. Adjuvant therapy first gained traction in the 1960s based on the "cell kill" hypothesis proposed by the mathematical biologist Skipper of the Southern Research Institute (as reported by DeVita and Chu 7 ). This theory held that systemic treatment killed a certain percentage of tumor cells proportional to the dose of chemotherapy rather than a constant number of cells. This concept resulted in a shift toward treatment with higher doses of chemotherapy, although the dosage is clearly limited by the toxicity and side effects of the therapy. This approach led to the consideration that systemic treatment could be more efficacious in patients with lower tumor burdensdin those patients who undergo surgery to remove the primary tumor and, therefore, are left only with micrometastatic disease. In the 1970s Fisher, 8 a breast cancer surgeon already challenging the field with minimally invasive lumpectomy, and Bonadonna 9 et al published nearly concurrent prospective studies on the efficacy of adjuvant therapy in patients with breast cancer, paving the way for the concept of adjuvant therapy in other malignancies.
Adjuvant Agents and Strategies in Other Malignancies
Adjuvant therapy has been extensively studied in other malignancies, including colorectal, cervical, gastric, head and neck, pancreatic, lung and ovarian cancers. 7 In some malignancies, such as early stage colon cancer, the role of adjuvant therapy is controversial. 10 However, in others, such as breast cancer, adjuvant therapy has a vital role in treatment and is selected by tumor specific factors and guided by patient preference. The magnitude of benefit varies by cancer and treatment type. Examples of successful adjuvant therapy in urological oncology include radiation therapy in prostate cancer with adverse pathological features following radical prostatectomy (HR 0.48 for biochemical recurrence), single dose carboplatin or radiotherapy in stage 1 seminoma (10.9% absolute risk reduction in recurrence) and platinum based chemotherapy in node positive penile cancer (HR 0.40 for overall survival).
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Identification of kidney cancer specific targets has led to the development of biological agents initially used in the metastatic setting that are now being evaluated as adjuvant treatments. However, an important consideration is how differences between metastatic and locally resected disease states affect the mechanism of action of adjuvant agents. For example inhibitors of the VEGF pathway in clear cell kidney cancer limit blood supply to the tumor and result in regression in some patients. However, this effect is often short lived, and progression is common, especially if the agent is discontinued. As explained by the "angiogenic switch" theory, 14 and hypothesized in a review by Chism and Rathmell, 15 19 Recent attempts to incorporate more advanced markers have been made. 20, 21 In an analysis of patients at our institution a 5-biomarker panel was identified from 170 patients with localized clear cell kidney cancer. 20 This panel was independently associated with DFS and, when combined with clinicopathological features, approached a concordance index of 0.91.
Rini et al recently developed a 16-gene biomarker assay, including genes associated with vasculogenesis, cell growth and division, immune response and inflammation, from nearly 1,000 nephrectomy patients. 21 The panel was predictive of cancer specific survival, DFS and OS, and could successfully identify high risk stage I to II tumors and low risk stage II to III tumors. The authors externally validated the recurrence score with a separate cohort of patients from France. However, the added cost of such biomarkers may limit widespread use.
Finally, with the wealth of available options molecular signatures may help guide specific adjuvant agent selection. However, currently there is no consensus on the optimal staging system for the purpose of clinical trial reporting. As a result, many of the adjuvant trials discussed in this review use different systems, which must be accounted for when interpreting and comparing results.
Risks of Adjuvant Therapy
The side effects of adjuvant therapies must not outweigh the benefits. While VEGF inhibitors have improved side effect profiles compared to traditional immunotherapies, high rates of adverse events are still reported in adjuvant trials to date. Even immune checkpoint inhibitors, which generally have toxicities favorable to chemotherapy, can have significant adverse effects. 22 While side effects may be tolerable in the setting of metastatic disease, they could be unacceptable in a patient receiving adjuvant treatment, who may, in fact, have no residual disease. This possibility is especially important since the duration of adjuvant therapy could potentially be lengthy or indefinite. Without improvements in patient selection allowing for reliable prediction of which patients are at greatest risk for recurrence adjuvant therapies may carry an overly burdensome risk without sufficient potential benefit.
TRADITIONAL IMMUNOTHERAPY Metastatic Disease
Early treatments for advanced and metastatic kidney cancer, such as chemotherapy, hormone therapy and radiation, were disappointing.
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Realization of the immune sensitivity of kidney cancer led to development of traditional immunotherapy, which initially consisted of IFN-a and later included HD IL-2. Up to 5% to 10% of appropriately selected patients treated with HD IL-2 will experience a complete response. However, this result comes at the cost of significant side effects, including capillary leak and cytokine release syndromes. 5 Although low, the complete response rates achieved with traditional immunotherapy for metastatic kidney cancer prompted its evaluation as adjuvant therapy for patients with high risk localized disease following surgical resection.
Adjuvant Setting
Unfortunately trials have revealed that traditional immunotherapy does not confer a survival benefit similar to adjuvant therapy. A randomized study by Pizzocaro et al found no difference in DFS or OS in 247 patients treated with IFN-a compared to controls. 26 A randomized study by Messing et al evaluating IFN-a vs observation also showed no difference in DFS or OS. 27 Clark et al evaluated HD IL-2 in a randomized study that closed early after an interim analysis demonstrated inability to meet the primary end point. 28 Studies combining traditional immunotherapies with other agents have similarly yielded negative results. 29 The most recent combination trial, published in 2014, randomized patients to low dose IL-2 and IFN-a or observation, and found no difference in DFS or OS. 30 Toxicities in these patients were significant, and more than half required vasopressor support for hypotension in 1 study. 28 Based on the prospective data available, traditional immunotherapy cannot be recommended as an adjuvant therapy in patients with completely resected high risk kidney cancer.
VEGF AND mTOR INHIBITORS
Background and Treatment for Metastatic Disease Discovery of the VHL tumor suppressor gene and its role in the pathophysiology of clear cell type kidney cancer established the foundation for the development of a revolutionary family of agents created to specifically target the newly discovered aberrant signaling pathway. Sorafenib and sunitinib, approved for advanced renal cell carcinoma in 2005 and 2006, respectively, are small molecule tyrosine kinase inhibitors that bind and inhibit the activation of the VEGF receptor and platelet-derived growth factor receptor located on endothelial cells. 31 VEGF inhibitors reduce the tumor driven angiogenesis needed to support tumor growth. Sunitinib and sorafenib supplanted traditional immunotherapy as first line treatment for metastatic kidney cancer by improving response rates, progression-free survival and OS. 32e34 The inhibitors of mTOR are a different but related class of molecules that function by ultimately impeding cell cycle regulators such as HIF-1a, c-MYC and cyclin-D1, and improve survival in VEGF refractory cases. 35 Novel VEGF and mTOR inhibitors, including pazopanib, axitinib, everolimus and cabozantinib, are being studied as second and third line options. 35e38 
Adjuvant Setting
Because of the efficacy of VEGF pathway targeted drugs in the metastatic space, their use as adjuvant treatment in patients at high risk for recurrence following surgical resection of localized kidney cancer has generated ongoing interest. The first trial to produce results was the ASSURE trial by Haas et al in 2016. 39 Shortly thereafter, Ravaud et al reported the results of S-TRAC. 6 The ASSURE trial randomized 1,943 patients 1:1:1 to sunitinib, sorafenib or placebo and revealed no difference in the primary end point of disease-free survival, or progression-free or overall survival. 39 By contrast, S-TRAC, which randomized 615 patients 1:1 to sunitinib or placebo, showed a significant improvement in the primary end point, DFS, from 5.6 years in the placebo group to 6.8 years in the sunitinib group. 6 In a subgroup analysis of higher risk patients the DFS benefit was longer by approximately 2.2 years. No OS benefit was demonstrated in S-TRAC with approximately 5 years of followup.
The discrepancies between the ASSURE trial and S-TRAC have resulted in some uncertainty regarding the benefit of adjuvant sunitinib, with advocates and skeptics focusing on methodological details as limitations of each study (table 1). The first key difference is the baseline risk of the study populations. ASSURE included patients with pT1b or greater grade 3 to 4 disease, whereas S-TRAC included more advanced locoregional (pT3 or greater) disease. In ASSURE more than a third of the patients had high grade T1 or T2 disease and would not have met inclusion in S-TRAC. This difference is reflected in the median DFS of the placebo groups, which was 1 year longer in ASSURE.
The higher risk population in S-TRAC more likely had micrometastatic disease and consequently more to gain from adjuvant therapy. Additionally approximately 20% of the ASSURE cohort had nonclear cell histology, whereas S-TRAC only included clear cell histology. Since nonclear cell histology kidney cancer is not driven by an aberrant VHL/HIF-1a pathway, VEGF inhibitors have resulted in poorer response rates when compared to clear cell kidney cancer. 40 This discrepancy could have masked differences in responses to VEGF inhibitors and, therefore, biased the study to a null result. However, a planned subset analysis of patients with clear cell histology only in the ASSURE trial failed to reveal a survival benefit.
Dosing adjustments made to improve tolerability in each study differed slightly. In ASSURE the dosages of sunitinib and sorafenib were decreased from 50 mg daily and 400 mg twice daily to 37.5 mg daily and 400 mg daily, respectively, in all patients starting in 2009. Dosages were increased as tolerated. In S-TRAC dose decreases of sunitinib by 12.5 mg were allowed but only a third of patients required dose reduction. The result was decreased drug exposure in ASSURE patients, potentially reducing the observed efficacy compared to the control group. However, both studies had high rates of dropout secondary to toxicity (44% in ASSURE and 45% in S-TRAC), underscoring issues with tolerability of these agents.
While each trial had similar primary end points, ASSURE relied on blinded investigator assessed end points, while S-TRAC end points were processed by independent central review. Blinded central review reduces imaging reader bias, which is particularly important in studies with VEGF inhibitors since characteristic side effects that are not seen in the placebo arm (eg hand, foot and mouth disease) could influence reader interpretation of the clinical end point.
With the results of S-TRAC and these potential confounders in mind Haas et al recently reported a subgroup analysis of pT3, pT4 and node positive patients in the ASSURE cohort. 41 No improvements in DFS or OS were found with sunitinib or sorafenib, even when stratified by dose quartiles. However, this analysis was not powered to detect differences in survival in this subgroup. Based on the currently available prospective data, patients most likely to derive a RFS benefit are those in the higher risk subgroups with clear cell histology. The possible benefits of adjuvant sunitinib should be discussed in the context of these discordant results and the potential for side effects.
Several ongoing randomized trials evaluating other VEGF inhibitors are expected to yield results in the coming years. The SORCE (Sorafenib in Treating Patients at Risk of Relapse after Undergoing Surgery to Remove Kidney Cancer, NCT00492258) trial is evaluating sorafenib in intermediate to high risk patients following surgery. Patients are randomly assigned to 1) placebo for 3 years, 2) sorafenib for 1 year followed by placebo for 2 years or 3) sorafenib for 3 years. The primary outcome is DFS, and results are pending. The ATLAS (Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients, NCT01599754) trial randomized patients with clear cell kidney cancer with pathological T3 to T4 or node positive disease to axitinib or placebo for 3 years. The EVEREST Renal Cell Carcinoma, NCT01235962) randomized high risk patients (high grade T2, any T3 to T4 or any N1 disease) with predominant clear cell disease to pazopanib or placebo for 1 year. Unfortunately this trial did not meet its primary end point based on information from the Novartis Web site, and presentation of the results is expected at an upcoming meeting. These studies will help to provide context for the results of ASSURE and S-TRAC. However, the data generated thus far indicate that patient selection may be a more important factor than potentially small differences in specific VEGF inhibitors.
VACCINES AND ANTIBODY DEPENDENT CYTOTOXIC AGENTS Autologous Vaccine Based Treatments
Given the known sensitivity of kidney cancer to immune based therapies, autologous vaccines have been studied extensively, most commonly in the metastatic setting but also as adjuvant treatment. There are several theoretical advantages of autologous whole-cell vaccines, including the formation of tumor specific immunity with limited cross-reactivity with normal tissue, limited preformed tolerance to tumor antigens and the ability to generate an immune response to multiple tumor antigens, limiting resistance secondary to mutations. 42 Based on positive data from a prospective trial of autologous tumor vaccines in colon cancer, Galligioni et al randomized 120 patients to receive an autologous tumor cell vaccine admixed with bacillus Calmette-Gu erin or observation. 43 Although the treated patients exhibited a delayed type of cutaneous hypersensitivity reaction at 1 month after vaccination to tumor cells but not autologous normal renal cells, no improvement in DFS or OS was found in the treatment group compared to the observation group.
Jocham et al also evaluated a post-nephrectomy renal tumor cell vaccine generated by inducing tumor cells in vitro with IFN-g to increase antigenicity before subcutaneous injection. 44 In that trial patients were randomized before nephrectomy to receive either vaccine treatment or standard of care observation. DFS was significantly improved in the treatment group compared to controls at 5 years (77.4% vs 67.8%, p ¼ 0.0204). Despite claiming that the intention to treat cohort yielded positive results, this trial has significant methodological issues. Nearly a third of patients were excluded after randomization secondary to pathologically benign disease, incorrect tumor stage and inability to prepare vaccine. Consequently the remaining cohort (called the intention to treat cohort by the authors) was a modified intention to treat cohort. Significant imbalances existed in this cohort. For example the treatment group had higher rates of clear cell histology among other differences that may have influenced the results. An updated report in 2006 failed to show an OS benefit. 42 The manufacturer of the vaccine, LipoNova AG (Hanover, Germany), filed for insolvency in 2008 and no further data on this strategy have been published.
Vitespen is a heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96) derived from a patient's nephrectomy specimen and used as a renal tumor vaccine. In a phase III study 818 patients were randomized to receive adjuvant vitespen or standard of care observation following nephrectomy for a wide spectrum of disease. 45 The vaccine consisted of an induction course of 4 weekly intradermal injections, followed by maintenance. At a median followup of 1.9 years there was no difference in recurrence between the vitespen and observation groups. A predefined subgroup analysis of patients with earlier stage disease yielded a trend toward improvement in RFS with adjuvant vitespen. However, the result was not statistically significant, and subsequent studies evaluating efficacy in this group have not yet been reported.
Antibody Dependent Cytotoxic Agents ARISER (Adjuvant RencarexÒ Immunotherapy Phase 3 Trial to Study Efficacy in Non-Metastatic Renal Cell Carcinoma), a recently published trial, was a placebo controlled, randomized study that treated patients with 6 months of girentuximab, a monoclonal antibody targeting CAIX, a cell surface receptor that is almost universally expressed in clear cell kidney cancers and correlates with poor prognosis. 46 Girentuximab generates an immune response, eliciting effector cells to destroy tumor cells in a process called antibody dependent cellular cytotoxicity. Unfortunately investigators found no benefit of adjuvant girentuximab. An unplanned post hoc analysis demonstrated an improvement in DFS in patients with the highest levels of CAIX expression, a finding that may become important as genetic and molecular patient selection criteria for adjuvant therapy gain traction. On further examination of patients with higher CAIX expression a DFS improvement was seen in those younger than 65 years old, those with lower tumor grades (grade 1 to 2) and an ECOG of 0.
IMMUNE CHECKPOINT INHIBITORS
Checkpoint inhibitors, such as antiprogrammed cell death-1 (eg nivolumab) and antiprogrammed cell death-ligand 1 (eg atezolizumab), are another promising class of cancer therapies that function by releasing the immune system from tumor driven T cell inhibition. 47 Checkpoint inhibitors are approved for a variety of malignancies, and have rapidly expanding approvals and indications in genitourinary malignancies.
Metastatic Disease
In the area of kidney cancer CheckMate025 (Study of Nivolumab [BMS-936558] vs Everolimus in PreTreated Advanced or Metastatic Clear-Cell Renal Cell Carcinoma, NCT01668784) is a recently published study comparing the checkpoint inhibitor nivolumab with the standard of care second line everolimus in a group of highly pretreated patients with metastatic clear cell kidney cancer. 48 Nivolumab was associated with an OS advantage of 5.4 months and subsequently gained approval as second line therapy. Importantly immunotherapy with checkpoint inhibitors is associated with significantly fewer side effects and an improved quality of life compared to standard agents. 49 As a result, several trials are under way evaluating checkpoint inhibitors as adjuvant therapy for patients with high risk localized kidney cancer. Risk of Developing Metastasis following  Nephrectomy, NCT03024996, table 2 ). Several critical trial design differences should be highlighted and will be important when analyzing and comparing results in the coming years.
PROSPER is a randomized study of neoadjuvant nivolumab followed by surgical treatment and additional adjuvant nivolumab compared to standard of care surgical treatment followed by observation. Investigators hypothesize that neoadjuvant nivolumab may "prime" the immune system when higher levels of tumor antigen are present before nephrectomy, ultimately resulting in improved micrometastatic tumor cell kill in the postnephrectomy adjuvant setting. Critics of this approach will point to the nonplacebo controlled comparator group, as well as logistical concerns with delays in treatment from neoadjuvant treatment compared to upfront surgery.
In IMmotion010 investigators have applied a more traditional placebo controlled, randomized approach using adjuvant atezolizumab, which may improve accrual in some practice settings compared to PROSPER. However, the benefits of immunotherapy with checkpoint inhibition are debated in the adjuvant only setting, given the relative lack of tumor antigen for treatment priming. This argument can also be applied to PROSPER, and calls into question whether a neoadjuvant only arm is required to determine the benefit of additional 
CONCLUSIONS
Patients at high risk for recurrence following surgical resection of localized kidney cancer pose a challenging clinical scenario for urologists and medical oncologists. Results from ASSURE and S-TRACT using adjuvant VEGF inhibitors are conflicting and ultimately highlight the limitations of targeted therapies in disease pathophysiology, underscoring the importance of optimal patient selection. Based on current data, patients with high risk locoregional clear cell kidney cancer may be offered the option of adjuvant sunitinib for 1 year following surgery in the context of known risk of side effects. We eagerly await the results of several adjuvant immune checkpoint inhibitor trials, given their promising efficacy and relative tolerability in the advanced setting. Future trials should incorporate advanced molecular and genetic markers of recurrence to treat micrometastatic disease early in those patients likely to benefit.
